Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS.
Michele Prato, Matteo Carminati, Filippo Frizzi, Greta Verri, Mattia Tondello, Barbara Barbini, Cristina Colombo, Zanardi Raffaella
Int J Psychiatry Clin Pract March 11, 2026 DOI: 10.1080/13651501.2026.2642680 via PubMed
Summary
AI-generated from the abstractIn a real-world clinical setting, intranasal esketamine and accelerated repetitive transcranial magnetic stimulation (rTMS) showed comparable effectiveness for treatment-resistant depression. Both treatments led to significant reductions in depressive symptoms, with no statistically significant difference between the two approaches. The findings suggest that either option can be a viable fast-acting intervention for patients who have not responded to prior treatments.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | Patients with treatment-resistant depression |
| Interventions | Intranasal Esketamine accelerated rTMS |
| Citations | 1 |
| Key finding | Intranasal esketamine and accelerated rTMS showed comparable real-world effectiveness for treatment-resistant depression. |
Abstract
Fast-acting approaches for treatment-resistant depression: real-world comparative effectiveness of Intranasal Esketamine versus accelerated rTMS.